{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:21:53Z","timestamp":1791397313613,"version":"4.3.3"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To summarize the clinical features, diagnosis and enzyme replacement therapy(ERT) of Fabry disease (FD) in children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinical data, laboratory tests, genetic variations and treatment of 10 FD children diagnosed in Shandong Provincial Hospital from September 2020 to June 2022 were retrospectively analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 10 cases from 6 families, 7 patients were boys of 4 to 13 years of age, and 3 were girls of 12 to 15 years of age. There were 7 symptomatic patients, including 6 boys and 1 girl. All 7 patients presented with acral neuralgia. Five patients had little or no sweating. Five patients presented with cutaneous angiokeratoma. Two patients had abdominal pain. One patient developed joint symptoms. Four patients had corneal opacity. One patient had hearing loss; one patient had short stature. One patient had mild proteinuria and 1 patient had dysplasia of the right kidney with decreased eGFR (55.28\u2005ml\/min.1.73\u2005m<jats:sup>2<\/jats:sup>). The left ventricular mass index was slightly elevated in 1 patient. Three patients had mild obstructive ventilatory dysfunction; a small amount of effusion in the intestinal space of the lower abdomen or mild fatty liver was found in 2 patients. Partial empty sella turcica in 1 patient. A total of 6 GLA gene variants were detected in 10 children, among which C.1059_1061delGAT (p.met353del) was a newly discovered mutation. Five children received ERT, of which 4 were treated with agalsidase beta and 1 was treated with agalsidase alpha. Only 1 patient had anaphylaxis. Lyso-GL-3 levels decreased significantly in the first 3 months of ERT initiation and remained relatively stable thereafter in 3 patients. The Lyso-GL-3 level was decreased, but renal impairment continued to progress in 1 patient treated with agalsidase alpha.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The clinical manifestations of FD in childhood are diverse, and it is necessary to make a definite diagnosis by combining family history, enzyme activity, biomarkers, gene testing and other indicators. Pedigree screening and high-risk population screening are helpful for early identification, early diagnosis and early treatment. No serious adverse reactions were found during the short-term treatment with agalsidase alpha and beta.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1084336","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T06:35:18Z","timestamp":1675406118000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical features and enzyme replacement therapy in 10 children with Fabry disease"],"prefix":"10.3389","volume":"11","author":[{"given":"Qian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minle","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenle","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and how to diagnose fabry disease in clinical pratice","volume":"360","author":"Michaud","year":"2020","journal-title":"Am J Med Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3760\/cma.j.cn112138-20201218-01028","article-title":"Expert consensus for diagnosis and treatment of fabry disease in China (2021)","volume":"60","year":"2021","journal-title":"Chin J Intern Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s11255-020-02546-3","article-title":"Fabry disease: where are we now?","volume":"52","author":"Turkmen","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus recommendations for diagnosis, management and treatment of fabry disease in paediatric patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin Genet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"129437","DOI":"10.1016\/j.bbagen.2019.129437","article-title":"Progress in the understanding and treatment of fabry disease","volume":"1864","author":"Miller","year":"2020","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"B7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","article-title":"Cardiac manifestations of anderson\u2013fabry disease in children and adolescents","volume":"97","author":"Kampmann","year":"2008","journal-title":"Acta Paediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jpeds.2005.03.004","article-title":"Radiological evidence of early cerebral microvascular disease in young children with fabry disease","volume":"147","author":"Cabrera-Salazar","year":"2005","journal-title":"J Pediatr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2326409816685735","article-title":"The challenge of diagnosis and indication for treatment in fabry disease","volume":"5","author":"Curiati","year":"2017","journal-title":"J Inborn Errors Metab Screen"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.jpeds.2009.07.003","article-title":"Guidelines to diagnosis and monitoring of fabry disease and review of treatment experiences","volume":"155","author":"Martins","year":"2009","journal-title":"J Pediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e12914","DOI":"10.1111\/ijcp.12914","article-title":"Time delays in the diagnosis and treatment of fabry disease","volume":"71","author":"Reisin","year":"2017","journal-title":"Int J Clin Pract"},{"key":"B13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3760\/cma.j.cn112140-20200902-00842","article-title":"Clinical features and enzyme replacement therapy in 4 children with fabry disease","volume":"59","author":"Lu","year":"2021","journal-title":"Chin J Pediatr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3969\/j.issn.1000-3606.2019.05.015","article-title":"Clinical features and genetic analysis of two cases with anderson- fabry syndrome","volume":"37","author":"Zhu","year":"2019","journal-title":"J Clin Pediatr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.neurol.2017.05.007","article-title":"Peripheral nerve involvement in Fabry's disease: Which investigations? A case series and review of the literature","volume":"173","author":"Franques","year":"2017","journal-title":"Rev Neurol (Paris)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tcm.2017.10.001","article-title":"Fabry disease: review and experience during newborn screening","volume":"28","author":"Hsu","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2215\/CJN.08091109","article-title":"Assessment of renal pathology and dysfunction in children with fabry disease","volume":"5","author":"Ramaswami","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13023-022-02215-x","article-title":"Expert opinion on the recognition, diagnosis and management of children and adults with fabry disease: a multidisciplinary Turkey perspective","volume":"17","author":"Ezgu","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/jhg.2016.52","article-title":"Fabry disease in patients with hypertrophic cardiomyopathy: a practical approach to diagnosis","volume":"61","author":"Seo","year":"2016","journal-title":"J Hum Genet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/cge.12261","article-title":"Intrafamilial phenotypic variability in four families with anderson-fabry disease","volume":"86","author":"Rigoldi","year":"2014","journal-title":"Clin Genet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3760\/cma.j.cn113694-20210430-00311","article-title":"Characteristics of neuralgia in patients with fabry disease in China","volume":"55","author":"Miao","year":"2022","journal-title":"Chin J Neuro"},{"key":"B22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0014-2999(01)01312-7","article-title":"Neuropathic pain in AndersonFabry disease: pathology and therapeutic options","volume":"429","author":"MacDermot","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.gene.2018.11.054","article-title":"High incidence of co-existing factors signifcantly modifying the phenotype in patients with fabry disease","volume":"687","author":"Koca","year":"2019","journal-title":"Gene"},{"key":"B25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"The management and treatment of children with fabry disease: a United States-based perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol Genet Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","article-title":"Fabry disease in children: agalsidase-beta enzyme replacement therapy","volume":"83","author":"Borgwardt","year":"2013","journal-title":"Clin Genet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the fabry outcome survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"B29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","article-title":"Agalsidase alfa versus agalsidase beta for the treatment of fabry disease: an international cohort study","volume":"55","author":"Arends","year":"2018","journal-title":"J Med Genet"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1084336\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T06:35:25Z","timestamp":1675406125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1084336\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":29,"alternative-id":["10.3389\/fped.2023.1084336"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1084336","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"article-number":"1084336"}}